Deep Learning in Drug Discovery and Diagnostics Market Report 2026

The deep learning in drug discovery and diagnostics market size has grown exponentially in recent years. It will grow from $10.58 billion in 2025 to $13.61 billion in 2026 at a compound annual growth rate (CAGR) of 28.7%. The growth in the historic period can be attributed to increasing availability of large biomedical datasets, rising computational power for model training, expansion of ai adoption in pharmaceutical R&D, growing demand for faster drug discovery cycles, early success of deep learning diagnostic models.

The deep learning in drug discovery and diagnostics market size is expected to see exponential growth in the next few years. It will grow to $36.96 billion in 2030 at a compound annual growth rate (CAGR) of 28.4%. The growth in the forecast period can be attributed to increasing investments in ai-based healthcare solutions, rising demand for precision medicine, expansion of ai adoption across clinical workflows, growing use of real-world evidence data, increasing regulatory acceptance of ai-assisted diagnostics. Major trends in the forecast period include increasing adoption of deep neural networks in drug screening, rising use of AI-driven predictive modeling in diagnostics, growing integration of multi-omics data analysis, expansion of automated clinical decision support systems, enhanced focus on personalized medicine platforms.

The increasing demand for personalized medicine is expected to drive the growth of the deep learning in drug discovery and diagnostics market in the coming years. Personalized medicine customizes medical treatments and interventions based on an individual’s genetic, environmental, and lifestyle factors to maximize effectiveness and minimize side effects. This demand is fueled by advancements in genomics and data analytics, which enable more precise and tailored treatments for patients. Deep learning enhances personalized medicine by analyzing complex biological data to identify specific biomarkers and predict patient responses to therapies more accurately. For example, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, reported that the FDA approved 16 new personalized therapies for rare disease patients in 2023, up from six in 2022. Therefore, the rising demand for personalized medicine is propelling the deep learning in drug discovery and diagnostics market.

Key companies in the deep learning in drug discovery and diagnostics market are increasingly adopting advanced technologies such as generative artificial intelligence (AI) and machine learning (ML)-driven automation platforms to enhance efficiency, reduce research and development (R&D) costs, and accelerate early-stage therapeutic discovery. Generative AI and ML-driven automation platforms are computational systems that analyze chemical and biological data to design new drug candidates virtually, predict molecular behavior, and automatically synthesize and test compounds using robotic systems, reducing reliance on traditional high-throughput screening methods. For instance, in July 2024, Exscientia, a UK-based AI-driven drug-design company, launched an AWS-powered AI/ML platform integrating a “DesignStudio” for AI-based molecule generation with an “AutomationStudio” for robotic synthesis and testing. The platform operates in a closed “design-make-test-learn” loop, where experimental data continuously refines AI models, accelerating discovery, improving scalability, and enabling more precise and cost-effective development of novel therapeutics.

In February 2024, Ginkgo Bioworks Holdings Inc., a US-based biotech company specializing in genetic engineering, acquired key assets of Reverie Labs for an undisclosed amount. Through this acquisition of Reverie’s infrastructure and AI/ML software for training large-scale foundation models, Ginkgo aims to enhance its AI-driven drug discovery services and accelerate the development of next-generation biological foundation models. Reverie Labs, a US-based company, has built and applied AI and ML tools to accelerate drug discovery processes.

Major companies operating in the deep learning in drug discovery and diagnostics market are Google Inc., Microsoft Corporation, International Business Machines Corporation, NVIDIA Corporation, Zebra Medical Vision Ltd, Tempus Labs Inc., Nanostring Technologies Inc., Owkin Inc., Insilico Medicine Inc., SOPHiA GENETICS SA, Qureai Technologies Pvt Ltd, H2Oai Inc., Arterys Inc., Deep Genomics Inc., GNS Healthcare Inc., MedAware Systems Inc., PathAI Inc., Kheiron Medical Technologies Ltd, CureMetrix Inc., OncoImmunity AS, Proscia Inc., BenevolentAI Ltd, BioXcel Therapeutics Inc.

North America was the largest region in the deep learning in drug discovery and diagnostics market in 2025. The regions covered in the deep learning in drug discovery and diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the deep learning in drug discovery and diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the deep learning in drug discovery and diagnostics market by increasing costs of imported high-performance computing hardware, specialized processors, data storage infrastructure, and advanced medical imaging equipment. Pharmaceutical and biotechnology companies in North America and Europe are most affected due to reliance on imported AI hardware and cloud infrastructure, while Asia-Pacific faces cost pressures in scaling computational capabilities. These tariffs are raising operational expenses and slowing infrastructure upgrades. However, they are also encouraging regional data center development, domestic AI hardware production, and localized innovation in optimized deep learning platforms.

The deep learning in drug discovery and diagnostics market research report is one of a series of new reports that provides deep learning in drug discovery and diagnostics market statistics, including deep learning in drug discovery and diagnostics industry global market size, regional shares, competitors with a deep learning in drug discovery and diagnostics market share, detailed deep learning in drug discovery and diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the deep learning in drug discovery and diagnostics industry. This deep learning in drug discovery and diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Deep learning in drug discovery and diagnostics involves the application of advanced neural networks and artificial intelligence (AI) techniques to analyze complex biological and chemical data, enabling the prediction of drug interactions, identification of disease patterns, and advancement of personalized medicine. It enhances drug discovery and diagnostics by increasing prediction accuracy, automating data analysis, and supporting personalized treatment through sophisticated examination of complex biological and chemical datasets.

The primary types of deep learning applications in drug discovery and diagnostics include drug discovery, diagnostics, forensic interventions, and others. Drug discovery leverages deep learning algorithms to analyze biological data and predict which drug compounds are likely to be effective. These algorithms accelerate the research process by identifying promising drug candidates and potential side effects at earlier stages. The drugs studied include small-molecule drugs and biologic drugs, which are utilized across various end-use sectors such as pharmaceutical companies, biotechnology firms, contract research organizations (CROs), and healthcare information technology (IT) providers.

The deep learning in drug discovery and diagnostics market consists of revenues earned by entities by providing services such as developing and integrating deep learning algorithms, analyzing large-scale biological and chemical data, offering software solutions and platforms, and consulting on AI-driven drug discovery and diagnostic strategies. The market value includes the value of related goods sold by the service provider or included within the service offering. The deep learning in drug discovery and diagnostics market also includes sales of software platforms and tools, machine learning frameworks, data analytics solutions, cloud-based computing services, hardware accelerators, and AI-driven diagnostic devices. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.